Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

NCT07789574 is registered in ClinicalTrials.gov with Thomas Ernst, PD Dr. med. as lead sponsor.

NCT NCT07789574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07789574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
Lead sponsor
Thomas Ernst, PD Dr. med.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 22, 2026
Completion date
December 31, 2030
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia (cml)